January 21, 2017 7:39 PM ET

Healthcare Equipment and Supplies

Company Overview of EKOS Corporation

Company Overview

EKOS Corporation engages in the development and clinical application of ultrasound infusion technologies for the treatment of vascular thrombosis. The company develops EkoSonic and MicroSonic SV endovascular devices for the controlled and selective infusion of physician-specified fluids, including thrombolytics into the peripheral vasculature. Its products are used by interventional radiologists, cardiologists, and cardiothoracic and vascular surgeons at various institutions around the world. The company was founded in 1995 and is based in Bothell, Washington. As of July 5, 2013, EKOS Corporation operates as a subsidiary of BTG International Inc.

11911 North Creek Parkway South

Bothell, WA 98011

United States

Founded in 1995





Key Executives for EKOS Corporation

Vice President and General Manager
Vice President of Regulatory & Clinical Affairs
Vice President of Systems Integration
Vice President of Operations
Compensation as of Fiscal Year 2016.

EKOS Corporation Key Developments

EKOS Corporation Announces the Publication of Results of the SEATTLE II Trial in the JACC: Cardiovascular Interventions

EKOS Corporation announced the publication of results of the SEATTLE II trial in the JACC: Cardiovascular Interventions. The study concluded that treatment with ultrasound-facilitated catheter-directed low-dose thrombolysis for acute pulmonary embolism (PE) improves right heart function, reduces blood clot size, and decreases pulmonary hypertension in patients with intermediate to high risk PE. Importantly, no patient experienced intracranial hemorrhage, a serious adverse experience related to full-dose thrombolysis treatment. The SEATTLE II study was a prospective, single-arm, multi-center trial designed to evaluate the safety and effectiveness of ultrasound-facilitated catheter-directed low-dose thrombolysis, using the EKOS EkoSonic® Endovascular System. One-hundred fifty (150) patients diagnosed as acute massive (N=31) or submassive (N=119) PE were enrolled. Patients received low dose (24 mg) of tPA (thrombolytic) for 24 hours with a unilateral catheter or for 12 hours with bilateral catheters. The size of the right heart measured as RV/LV ratio significantly decreased from 1.55 to 1.13 (p<0.0001) by 48 hours after start of treatment. For patients with severe PE, the mortality rate is nearly one third1. In the SEATTLE II study 31 patients presented to the emergency room with massive PE, syncope and hypotension. All 31 survived the 30-day follow up period. Of 150 patients in the study, one death was directly attributed to PE. There were no intracranial hemorrhages and no fatal bleeding events. Major bleeds occurred in 15 patients and were comprised of one severe bleed and 16 moderate bleeds. Six of the major bleeds occurred in patients with co-morbidities known to be associated with an increased risk of bleeding during thrombolytic therapy.

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems, Inc. United States
20/20 Imaging LLC United States
21st Century Scientific, Inc. United States
21X Corporation United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact EKOS Corporation, please visit www.ekoscorp.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.